Multi-System Inflammatory Syndrome in Children (MIS-C) Following SARS-CoV-2 Infection : Review of Clinical Presentation, Hypothetical Pathogenesis, and Proposed Management
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection may result in the multisystem inflammatory syndrome in children (MIS-C). The clinical presentation of MIS-C includes fever, severe illness, and the involvement of two or more organ systems, in combination with laboratory evidence of inflammation and laboratory or epidemiologic evidence of SARS-CoV-2 infection. Some features of MIS-C resemble Kawasaki Disease, toxic shock syndrome, and secondary hemophagocytic lymphohistiocytosis/macrophage activation syndrome. The relationship of MIS-C to SARS-CoV-2 infection suggests that the pathogenesis involves post-infectious immune dysregulation. Patients with MIS-C should ideally be managed in a pediatric intensive care environment since rapid clinical deterioration may occur. Specific immunomodulatory therapy depends on the clinical presentation. The relationship between the immune response to SARS-CoV-2 vaccines in development and MIS-C requires further study.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:7 |
|---|---|
| Enthalten in: |
Children (Basel, Switzerland) - 7(2020), 7 vom: 01. Juli |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Nakra, Natasha A [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Revised 29.03.2024 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3390/children7070069 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM312078846 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM312078846 | ||
| 003 | DE-627 | ||
| 005 | 20240329233301.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/children7070069 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1354.xml |
| 035 | |a (DE-627)NLM312078846 | ||
| 035 | |a (NLM)32630212 | ||
| 035 | |a (PII)E69 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Nakra, Natasha A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Multi-System Inflammatory Syndrome in Children (MIS-C) Following SARS-CoV-2 Infection |b Review of Clinical Presentation, Hypothetical Pathogenesis, and Proposed Management |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 29.03.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection may result in the multisystem inflammatory syndrome in children (MIS-C). The clinical presentation of MIS-C includes fever, severe illness, and the involvement of two or more organ systems, in combination with laboratory evidence of inflammation and laboratory or epidemiologic evidence of SARS-CoV-2 infection. Some features of MIS-C resemble Kawasaki Disease, toxic shock syndrome, and secondary hemophagocytic lymphohistiocytosis/macrophage activation syndrome. The relationship of MIS-C to SARS-CoV-2 infection suggests that the pathogenesis involves post-infectious immune dysregulation. Patients with MIS-C should ideally be managed in a pediatric intensive care environment since rapid clinical deterioration may occur. Specific immunomodulatory therapy depends on the clinical presentation. The relationship between the immune response to SARS-CoV-2 vaccines in development and MIS-C requires further study | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Kawasaki Disease | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a hemophagocytic lymphohistiocytosis | |
| 650 | 4 | |a macrophage activation syndrome | |
| 650 | 4 | |a multisystem inflammatory syndrome in children (MIS-C) | |
| 650 | 4 | |a toxic shock syndrome | |
| 700 | 1 | |a Blumberg, Dean A |e verfasserin |4 aut | |
| 700 | 1 | |a Herrera-Guerra, Angel |e verfasserin |4 aut | |
| 700 | 1 | |a Lakshminrusimha, Satyan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Children (Basel, Switzerland) |d 2014 |g 7(2020), 7 vom: 01. Juli |w (DE-627)NLM246337737 |x 2227-9067 |7 nnns |
| 773 | 1 | 8 | |g volume:7 |g year:2020 |g number:7 |g day:01 |g month:07 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/children7070069 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 7 |j 2020 |e 7 |b 01 |c 07 | ||